Study With a Topical Gel to Treat Common Warts in Adults

Graceway Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Warts

Treatments: Drug: Resiquimod

Study type: Interventional

Funder types: Industry

Identifiers

NCT00117871

1515-RESI

Details and patient eligibility

About

The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.

A second purpose is to evaluate the safety of the drug.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of common warts
• Two forms of birth control

Exclusion criteria

• Pregnant or breast feeding
• Other types of warts, ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind